Introduction {#s1}
============

Testicular cancer (TC), which represents 1% of male neoplasms and 5% of urological tumors, is the most common solid cancer in men between 20 and 45 years old ([@B1], [@B2]). With over 9,560 new cases diagnosed each year in the United States (US), the incidence of TC has been on the rise for the last 10 years, especially in more economically-developed areas ([@B2]--[@B5]). For metastatic TC (mTC), the treatment load of platinum-based chemotherapy is usually associated with cure rate. Inappropriate systemic treatment can result in a low rate of cure, whereas overtreatment may lead to acute and late adverse events ([@B6], [@B7]). In this regard, characterizing mTC into different groups based on variant clinical outcome is indispensable.

Many factors have been demonstrated as contributing to the prognosis of advanced TC, and metastatic site has an important role in many malignancies ([@B8], [@B9]). The favorable prognostic impact of lung is widely known based on the data from the International Germ Cell Cancer Collaborative Group (IGCCCG) ([@B10]). However, several drawbacks limit the generalizability of previous data in contemporary populations. For example, historical cohorts were evaluated in this study, and only a small proportion of the patients received the current standard chemotherapy ([@B10]). Furthermore, despite TC tending to spread to sites including lung and distant lymph nodes, the risk of atypical metastases is not negligible ([@B10], [@B11]). Approximately 9--11% of the patients with mTC have atypical metastases (non-pulmonary) ([@B10], [@B11]). However, little is known about the prognostic value of non-pulmonary metastases since limited data exists on the previous findings ([@B10]--[@B15]). Consequently, to address this lack of knowledge and to investigate the potential prognostic value of site-specific metastases in TC, we studied the association of survival outcome and prognostic value with different metastatic sites in patients with metastatic cancer in a retrospective metastatic TC cohort from the US.

Methods {#s2}
=======

Cohort Selection and Data Collection
------------------------------------

A retrospective metastatic TC cohort including patients with primary mTC (M1 stage) from 2010 to 2016 was selected from the Surveillance, Epidemiology and End Results (SEER) program dataset. Additional inclusion criteria were as follows: patients must be no \<14 years old of age; TC was the primary diagnosis of cancer; distant metastatic sites must be documented, including distant lymph nodes, lung, liver, bone, and brain; patient received active follow-up; and patients had a survival length ≥ 1 month. We excluded patients with insufficient data of pathological characteristics, distant metastases, M1 stage, extragonadal germ cell tumor, and data of survival outcomes. Patients with controversial data (e.g., patients at M1a stage without metastases of lung or distant lymph nodes) were also excluded from the cohort ([Figure S1](#SM1){ref-type="supplementary-material"}). Covariates such as metastatic sites, surgery of primary tumor, TNM stage, serum tumor markers after orchiectomy, and pathological characteristics were included in the analysis. Survival time (months), the status of survival, and cause of death were also included in the analysis. S stage was obtained according to different level of patient\'s postoperative tumor markers including alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH) based on the staging system of the 2016 Tumor, Node, Metastasis (TNM) of the International Union Against Cancer (UICC). Data such as systemic therapy, radiation therapy, and surgery of metastatic site were not available in the database. Unless specifically emphasized, distant lymph nodes generally refer to following three conditions: (1) retroperitoneal lymph nodes specified as above the diaphragm; (2) external iliac nodes, pelvic nodes and inguinal nodes without or unknown previous scrotal or inguinal surgery prior to presentation of the testis tumor; (3) other kinds of metastatic distant lymph nodes. It is worth noting that external iliac nodes, pelvic nodes as well as inguinal nodes with previous scrotal or inguinal surgery prior to presentation of the testis tumor were classified as regional nodes. And retroperitoneal nodes below the diaphragm, nodes around spermatic vein, periaortic nodes, and pericaval nodes were also classified as regional lymph nodes.

Study Outcomes
--------------

Overall survival (OS) and cancer-specific survival (CSS) were the two major outcomes of this study. OS was defined as the interval of time from TC diagnosis to death. CSS was defined as the interval from the date of TC diagnosis to death due to TC or other causes.

Statistical Analysis
--------------------

Demographic factors were reported as mean, median, and interquartile range for continuous variables, and frequency and proportion for categorical variables. Comparisons of means and proportions were analyzed by the Student\'s *t*-test and Chi-squared test, respectively. Survival was analyzed by the Kaplan-Meier survival analysis. Breslow test as well as log-rank test were performed to analyze the discrepancies between OS and CSS. A Cox proportional model with hazard ratios and 95% CI was then implemented for multivariate analyses of the cohort. All statistical analyses were performed using SPSS Statistics software version 20.0 (IBM, NY, US).

Results {#s3}
=======

Demographic and Clinical Characteristics
----------------------------------------

Overall, 1,661 patients with mTC were enrolled in the current study, and were identified according to our defined inclusion and exclusion criteria ([Figure S1](#SM1){ref-type="supplementary-material"}). Patients\' demographical characteristics are shown in [Table 1](#T1){ref-type="table"}. The average age at diagnosis was 33.2 years, with a median of 31 years. There was no significant difference in the distribution of the number of patients in each year (from 2010 to 2016). Most of the population (90.4%) was ethnically white. More than two-thirds of the patients were unmarried. Primary TC on the right side was more common than on the left side. Approximately 84.3% of patients underwent radical orchiectomy. Patients\' clinicopathological information are also summarized in [Table 1](#T1){ref-type="table"} according to histological type. Since the number of patients (*n* = 80) with non-germ cell testicular cancer (NGCTC) was too small, these individuals were not listed separately in [Table 1](#T1){ref-type="table"}. It is notable that patients with seminoma were older than those with non-seminomatous germ cell tumor (NSGCT) (*P* \< 0.001).

###### 

Characteristics of patients and metastatic sites.

  **Characteristics**           **Total (*n* = 1,661)**   **Seminoma (*n* = 403)**   **NSGCT (*n* = 1,178)**
  ----------------------------- ------------------------- -------------------------- -------------------------
  Age at diagnosis, years                                                            
    Mean (median)               33.2 (31)                 40.7 (40)                  30.6 (28)
    IQR                         24--40                    32--50                     23--36
  Year of diagnosis                                                                  
    2010                        213 (12.9)                42 (10.4)                  165 (14.0)
    2011                        235 (14.1)                71 (17.6)                  152 (12.9)
    2012                        238 (14.3)                63 (15.6)                  167 (14.2)
    2013                        278 (16.7)                80 (19.9)                  181 (15.4)
    2014                        240 (14.4)                63 (15.6)                  164 (13.9)
    2015                        229 (13.8)                42 (10.4)                  173 (14.7)
    2016                        228 (13.7)                42 (10.4)                  176 (14.9)
  Race                                                                               
    White                       1,501 (90.4)              367 (91.1)                 1,066 (90.5)
    Black                       58 (3.5)                  16 (4.0)                   40 (3.4)
    Others                      91 (5.5)                  16 (4.0)                   65 (5.5)
    Unknown                     11 (0.7)                  4 (1.0)                    7 (0.6)
  Marital status                                                                     
    Married                     459 (27.6)                160 (39.7)                 274 (23.3)
    Unmarried                   1,140 (68.6)              226 (56.1)                 863 (73.3)
    Unknown                     62 (3.7)                  17 (4.2)                   41 (3.5)
  T stage                                                                            
    T0                          72 (4.3)                  37 (9.2)                   33 (2.8)
    T1                          534 (32.1)                119 (29.5)                 390 (33.1)
    T2                          444 (26.7)                74 (18.4)                  337 (28.6)
    T3                          281 (16.9)                42 (10.4)                  233 (19.8)
    T4                          39 (2.3)                  14 (3.5)                   23 (2.0)
    Tx                          291 (17.5)                117 (29.0)                 162 (13.8)
  N stage                                                                            
    N0                          516 (31.1)                125 (31.0)                 356 (30.2)
    N1                          436 (26.2)                94 (23.3)                  323 (27.4)
    N2                          239 (14.4)                32 (7.9)                   197 (16.7)
    N3                          365 (22.0)                120 (29.8)                 232 (19.7)
    Nx                          105 (6.3)                 32 (7.9)                   70 (5.9)
  S stage                                                                            
    S0                          146 (8.8)                 38 (9.4)                   103 (8.7)
    S1                          210 (12.6)                31 (7.7)                   173 (14.7)
    S2                          189 (11.4)                32 (7.9)                   145 (12.3)
    S3                          179 (10.8)                28 (6.9)                   137 (11.6)
    Sx                          937 (56.4)                274 (68.0)                 620 (52.6)
  Laterality                                                                         
    Left-origin of primary      725 (43.6)                165 (40.9)                 527 (44.7)
    Right-origin of primary     812 (48.9)                177 (43.9)                 593 (50.3)
    Bilateral, single primary   4 (0.2)                   0 (0.0)                    3 (0.3)
    unknown                     120 (7.2)                 61 (15.1)                  55 (4.7)
  Radical orchiectomy                                                                
    Yes                         1,401 (84.3)              296 (73.4)                 1,034 (87.8)
    No                          243 (14.6)                102 (25.3)                 132 (11.2)
    Unknown                     17 (1.0)                  5 (1.2)                    12 (1.0)

*IQR, interquartile range; NSGCT, non-seminomatous germ cell tumor*.

Distribution of Distant Metastases
----------------------------------

The distributions and discrepancies in the sites of metastases of TC patients are illustrated in the Venn diagram of [Figure 1](#F1){ref-type="fig"}. The most common sites of metastases were lung (1,029 cases, 61.9%), followed by distant lymph nodes (601 cases, 36.2%), liver (252 cases, 15.2%), bone (112 cases, 6.7%), and brain (106 cases, 6.4%). Most patients (953, 57.4%) had a single site of distant metastases, followed by two sites (444, 26.7%), three sites (73, 4.4%), and four sites (10, 0.6%). No more than four metastatic sites were found in any one case of the cohort. When classified according to histological type, the distribution was different than that of metastases in TC patients ([Figures S2A, S2B](#SM2){ref-type="supplementary-material"}). Patients with seminoma usually had distant lymph node metastases (199 cases, 49.4%), followed by that to lung (108 cases, 26.8%) ([Figure S2A](#SM2){ref-type="supplementary-material"}). Furthermore, patients with NSGCT were more likely to have metastases to lung (855 cases, 72.5%), followed by distant lymph nodes (385 cases, 32.6%) ([Figure S2B](#SM2){ref-type="supplementary-material"}).

![Venn diagram of the distribution of distant metastatic sites in the overall cohort.](fonc-09-01495-g0001){#F1}

Associations Between Metastatic Sites and Survival Outcomes
-----------------------------------------------------------

Since it is commonly acknowledged that patients with distant lymph node metastases have favorable prognoses, we took distant lymph node metastases as a reference and patients with a single metastatic site were included in the Kaplan-Meier analysis (*n* = 947). Patients with brain metastases were excluded in the analysis of patients with only one metastasis due to insufficient samples (only six patients). In [Figures 2A--F](#F2){ref-type="fig"}, it was consistent with clinical experience that patients diagnosed with liver, lung, and bone metastases had worse outcomes in the measurement of both OS and CSS, compared with those with distant lymph node metastases alone. Using log-rank test to compare the number of metastatic sites in all patients (*n* = 1,661) with TC, significantly longer OS and CSS was observed in patients with one metastatic site than those with more metastases (OS: HR = 2.196, 95% CI = 1.760--2.739; CSS: HR = 2.492, 95% CI = 1.964--3.162; both *P* \< 0.001) ([Figures 3A,B](#F3){ref-type="fig"}) In the subgroup of patients with only one metastatic site (*n* = 947), patients with lymph node and lung metastases showed significantly longer OS and CSS compared with bone and liver metastases by log-rank comparison (*P* \< 0.001) ([Figures 4A,B](#F4){ref-type="fig"}). Since curves of liver metastases and bone metastases crossed with each other in the Kaplan-Meier analysis, comparisons between liver and bone metastases required further multivariable Cox regression analysis.

![Kaplan-Meier curves of overall survival and cancer-specific survival in patients with liver **(A,B)**, lung **(C,D)**, and bone **(E,F)** metastases vs. patients with distant lymph node metastasis.](fonc-09-01495-g0002){#F2}

![Kaplan-Meier curves of overall survival **(A)** and cancer-specific survival **(B)** according to the number of metastatic sites.](fonc-09-01495-g0003){#F3}

![Kaplan-Meier curves of overall survival **(A)** and cancer-specific survival **(B)** according to the site of metastasis in patients with a single metastatic site.](fonc-09-01495-g0004){#F4}

Multivariable Cox Regression Models
-----------------------------------

Parameters besides histology, T stage, N stage, S stage, and site of metastases were included in the multivariable Cox regression model of single-site metastasis patients. As shown in [Table 2](#T2){ref-type="table"}, histology, T stage, and metastatic site were independent prognostic factors for mTC patients both in OS and CSS (all *P* \< 0.05). S stage was a prognostic factor only for CSS (*P* = 0.016). However, it still showed a trend in predicting OS (*P* = 0.052). N stage showed no statistical difference in predicting OS and CSS of mTC patients. In the analysis of metastatic sites, bone and liver represented the two groups with the worst prognosis of OS and CSS (all *P* \< 0.05) ([Table 2](#T2){ref-type="table"}). Lung and brain metastases did not achieve statistical difference.

###### 

Multivariable Cox regression analysis predicting overall survival and cancer-specific-survival in 953 patients diagnosed with a single metastatic site within the SEER database between 2010 and 2016.

  **Characteristics**   **Overall survival**    **Cancer specific survival**                           
  --------------------- ----------------------- ------------------------------ ----------------------- ---------
  Histology                                     0.001                                                  \<0.001
   Seminoma             Reference                                              Reference               
   NSGCT                1.410 (0.919--2.163)    0.115                          1.817 (1.102--2.999)    0.019
   NGCTC                3.578 (1.856--6.894)    \<0.001                        4.958 (2.421--10.155)   \<0.001
  T stage                                       0.009                                                  0.013
   T0--T2               Reference                                              Reference               
   T3--T4               1.416 (0.943--2.127)    0.094                          1.452 (0.925--2.279)    0.105
   Tx                   1.915 (1.123--2.967)    0.004                          1.973 (1.222--3.187)    0.005
  N stage                                       0.850                                                  0.707
   N0                   Reference                                              Reference               
   N1--N2               1.029 (0.701--1.510)    0.886                          0.858 (0.561--1.312)    0.478
   N3                   1.197 (0.767--1.871)    0.429                          1.119 (0.689--1.817)    0.650
   Nx                   0.960 (0.440--2.092)    0.918                          1.066 (0.483--2.350)    0.875
  S stage                                       0.052                                                  0.016
   S0                   Reference                                              Reference               
   S1                   1.697 (0.696--4.136)    0.245                          0.846 (0.283--2.527)    0.764
   S2                   1.874 (0.761--4.613)    0.172                          1.947 (0.745--5.090)    0.174
   S3                   3.352 (1.423--7.893)    0.006                          3.228 (1.280--9.142)    0.013
   Sx                   2.169 (1.001--4.698)    0.050                          2.113 (0.916--4.874)    0.080
  Site of metastases                            0.029                                                  0.004
   Lung only            1.312 (0.868--1.983)    0.198                          1.417 (0.880--2.281)    0.151
   Liver only           2.265 (1.238--4.145)    0.008                          2.843 (1.473--5.487)    0.002
   Bone only            2.419 (1.190--4.919)    0.015                          3.074 (1.424--6.636)    0.004
   Brain only           1.622 (0.221--11.913)   0.635                          2.642 (0.354--19.691)   0.343
   Distant nodes only   Reference                                              Reference               

*HR, hazard ratio; NSGCT, non-seminomatous germ cell tumor; NGCTC, non-germ cell testicular cancer*.

Subgroup Analysis Based on Histological Type
--------------------------------------------

Among mTC patients with single metastases, a total of 251 patients with seminoma and 655 patients with NSGCT were included in the subgroup analysis, while patients with brain metastases were excluded (*n* = 6).

For patients with NSGCT, bone and liver metastases showed worse outcome than lung and distant lymph node metastases both in OS and CSS (both *P* \< 0.001) ([Figures 5C,D](#F5){ref-type="fig"}). The same results could be validated in multivariable Cox models ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). Especially, bone metastases showed a worst outcome compared with the other three types of metastases (OS: HR = 5.116, 95% CI = 2.031--13.884; CSS: HR = 5.243, 95% CI = 1.900--14.466; both *P* = 0.001).

![Kaplan-Meier curves of overall survival and cancer-specific survival in patients with seminoma **(A,B)** and non-seminomatous germ cell tumor **(C,D)** according to the site of metastasis in patients with a single metastatic site.](fonc-09-01495-g0005){#F5}

###### 

Multivariable Cox regression analysis predicting overall survival in patients of different histological type diagnosed with a single metastatic site within the SEER database between 2010 and 2016.

  **Characteristics**    **Seminoma**            **NSGCT**                           
  ---------------------- ----------------------- ----------- ----------------------- -------
  T stage                                        0.096                               0.038
    T0--T2               Reference                           Reference               
    T3--T4               1.648 (0.627--4.328)    0.311       1.285 (0.792--2.085)    0.309
    Tx                   2.353 (1.079--5.130)    0.031       2.024 (1.168--3.506)    0.012
  S stage                                        0.715                               0.108
    S0                   Reference                           Reference               
    S1                   4.727 (0.525--42.563)   0.166       1.274 (0.470--3.453)    0.634
    S2                   2.690 (0.241--30.004)   0.421       1.571 (0.580--4.256)    0.375
    S3                   3.694 (0.370--36.888)   0.266       2.892 (1.140--7.339)    0.025
    Sx                   2.994 (0.400--22.417)   0.286       1.650 (0.708--3.849     0.246
  Site of metastases                             0.453                               0.004
    Lung only            1.206 (0.522--2.787)    0.661       1.321 (0.794--2.198)    0.283
    Liver only           2.176 (0.783--6.050)    0.136       1.922 (0.864--4.273)    0.109
    Bone only            0.735 (0.169--3.202)    0.681       5.116 (2.031--13.884)   0.001
    Distant nodes only   Reference                           Reference               

*HR, hazard ratio; NSGCT, non-seminomatous germ cell tumor*.

###### 

Multivariable Cox regression analysis predicting cancer-specific-survival in patients of different histological type diagnosed with a single metastatic site within the SEER database between 2010 and 2016.

  **Characteristics**    **Seminoma**             **NSGCT**                           
  ---------------------- ------------------------ ----------- ----------------------- -------
  T stage                                         0.209                               0.049
    T0--T2               Reference                            Reference               
    T3--T4               1.108 (0.297--4.131)     0.879       1.353 (0.802--2.284)    0.257
    Tx                   2.182 (0.891--5.345)     0.088       2.046 (1.135--3.687)    0.017
  S stage                                         0.820                               0.083
    S0                   Reference                            Reference               
    S1                   1.001 (0.997--1.211)     0.981       0.830 (0.253--2.725)    0.759
    S2                   2.6787 (0.238--30.098)   0.425       1.720 (0.587--5.046)    0.323
    S3                   3.922 (0.388--39.670)    0.247       2.844 (1.026--7.883)    0.044
    Sx                   2.156 (0.281--16.523)    0.460       1.737 (0.689--4.381)    0.242
  Site of metastases                              0.492                               0.005
    Lung only            1.184 (0.411--3.407)     0.754       1.359 (0.772--2.393)    0.287
    Liver only           2.553 (0.777--8.391)     0.123       2.379 (1.033--5.482)    0.042
    Bone only            1.122 (0.245--5.145)     0.882       5.243 (1.900--14.466)   0.001
    Distant nodes only   Reference                            Reference               

*HR, hazard ratio; NSGCT, non-seminomatous germ cell tumor*.

For patients with seminoma, although there was no statistical difference in the Kaplan-Meier analysis, it still showed a certain trend that liver metastases indicated the worst outcome than the other three types of metastases both in OS and CSS ([Figures 5A,B](#F5){ref-type="fig"}). Subsequent Cox models showed the same trend, although they also did not meet statistical significance ([Table 4](#T4){ref-type="table"}). Interestingly, patients with bone metastases show similar survival trend as lung and lymph node metastases.

Discussion {#s4}
==========

Prognostic system of testicular cancer proposed by IGCCCG is widely used. However, data of the IGCCCG (the largest available dataset) were accumulated from 1975 to 1990, and only a small proportion of patients received a bleomycin, etoposide, and cisplatin (BEP)-based regimens. Currently, BEP-based regimen is the main standard chemotherapy for advanced TC, which is superior to other combinations of chemotherapy agents ([@B16]). Therefore, many researches questioned the prognostic value of IGCCCG model in current population. Up to now, few studies have systematically focused on the association between metastatic sites and survival in the post-BEP era ([@B12], [@B17]). Our study is the first to comprehensively address the role of the metastatic site on TC patients\' survival using a contemporary cohort with a large sample size. We found different metastatic profiles exist in mTC patients. Patients with seminoma tend to metastasize to distant nodes, while patients with NSGCT often develop pulmonary metastases. Notably, our study provided additional information on site-specific survival for distant metastases.

Previous studies about the impact of metastatic sites on prognosis of mTC often enrolled all metastatic populations and impact of different metastatic sites on survival often affect each other ([@B10], [@B18]). Since many people involves in multiple metastatic sites, it is difficult to accurately describe the impact of metastatic sites on survival.

Therefore, for the first time we conducted further analyses using a subgroup of patients with a single metastatic site. We revealed that bone and liver metastases represent the two worst survival outcomes in all mTC patients, while lung and distant nodes metastases indicate better survival than other kind of metastases. We attributed the lack of statistical difference in patients with brain metastases to the sample size (*n* = 6). However, categorization of the patients according to histological type resulted in different observations. For patients with NSGCT, distant lymph node and lung metastases showed the best two outcomes compared with bone and liver metastases, in line with the IGCCCG database. However, for patients with seminoma, bone metastases showed a similar survival trend compared with lung and distant lymph node metastases. Liver tends to bare the worst survival outcome alone. Interestingly, subgroup analysis of IGCCCG also reveal a higher 5-year survival rate of patients of seminoma with bone metastases than that of lung ([@B10]). Consequently, we suppose that the prognosis of site-specific metastases should be carefully revalued in the contemporary cohort according to histological type. In this study, we also found that more sites of metastases were associated with poorer clinical outcomes, which is easy to understand. A greater number of metastatic sites commonly suggest more aggressive biological behavior of the tumor and worse physical conditions.

Several clinical implications should be highlighted in the current study. On one hand, our results might inspire physicians to develop novel therapeutic approaches through a better understanding of the natural history of TC. On the other hand, our findings highlight the need to improve the risk stratification of metastatic patients for identifying candidate for clinical trials ([@B19], [@B20]).

Despite our current study identifying the association of prognostic outcomes with different metastatic sites in patients with metastatic cancer in a large retrospective TC cohort, it does have some limitations. First, the retrospective nature of our datasets may lead to incomplete or even contradictory clinical information. Second, our analyses were prevented from adjusting for potential confounders due to the lack of information regarding systemic treatment regimens or surgery toward metastatic sites, which may impact prognosis of patients ([@B21]).

Conclusion {#s5}
==========

There is much heterogeneity regarding oncological outcomes in site-specific metastatic patients. Different metastatic profiles and different prognostic values of metastases exist in TC patients depending on histological type. Distant lymph nodes and lung metastases are favorable prognostic factors, while liver metastases indicate negative survival outcomes in TC.
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Flow chart of inclusion and exclusion of patients. SEER, Surveillance, Epidemiology, and End Results.
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**(A)** Venn diagram of the distribution of distant metastatic sites in patients with seminoma. **(B)** Venn diagram of the distribution of distant metastatic sites in patients with non-seminomatous germ cell tumor.
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